Lifeboat Foundation

Very eye opening: North America has the largest market for silent cancer therapeutic, followed by Europe.

Silent cancer refers to those types of cancer which are undiagnosed in early stages. This is due to asymptomatic nature of the disease which makes it difficult to identify the disease till it progresses to advanced stages. Major silent types of cancer include brain, cervix, esophagus, mouth and larynx, ovarian, pancreatic, kidney, and liver cancer. Some silent types of cancer such as ovarian cancer, esophageal cancer, and pancreatic cancer show symptoms in their early stages. Ovarian cancer occurs in epithelium or lining cells of the ovary. Major signs and symptoms of ovarian cancer include pain or cramps in the belly, nausea, abnormal vaginal bleeding, and bloating. Pancreatic cancer is one of the fastest growing types of cancer worldwide. Esophagus cancer is more common among the older population, compared to adults. This cancer is mainly treated by chemotherapy, surgery, and radiosurgery. Moreover, physicians also use combination therapy for the treatment of silent cancer. For instance, the combination of radiation therapy and chemotherapy is very effective in the treatment of silent cancer.

Continue reading “Silent Cancer Therapeutic Market — Historical, Current and Projected industry size and Recent Industry Trends by 2015 — 2021” »

New project underway to find answers.

The Allen Institute for Brain Science has announced major updates to its online resources available at “brain-map.org” brain-map.org, including a new resource on Aging, Dementia and Traumatic Brain Injury (TBI) in collaboration with UW Medicine researchers at the University of Washington, and Group Health. The resource is the first of its kind to collect and share a wide variety of data modalities on a large sample of aged brains, complete with mental health histories and clinical diagnoses.

“The power of this resource is its ability to look across such a large number of brains, as well as a large number of data types,” says Ed Lein, Ph.D., Investigator at the Allen Institute for Brain Science. “The resource combines traditional neuropathology with modern ‘omics’ approaches to enable researchers to understand the process of aging, look for molecular signatures of disease and identify hallmarks of brain injury.”

Continue reading “Allen Institute releases powerful new data on the aging brain and traumatic brain injury” »

I learn useful life lessons from each patient I meet. Some are positive messages, reminding me of the importance of maintaining balance between family, work, and leisure activities, but more frequently I witness examples of the remarkable resilience of the human spirit when facing the reality and risks of a major surgical procedure and a diagnosis of cancer. Rarely, patients and their family members utter remorseful or simply sad remarks when they are faced with a grim prognosis and the emotions associated with an onrushing date with mortality. These comments invariably involve an inventory of regrets in life, including, “I should have spent more time with my kids,” “I wish I had told my father (or mother, brother, sister, child, or some other person) that I loved them before they died,” and “I have spent my entire life working, I never took time for anything else.” I wince when I hear these openly expressed remonstrations, I recognize that I am hearing painful and heartfelt truths. Not a week goes by that I am not reminded that I do not one day want to look back at my life with a long list of regrets, should have dones, and what ifs.

I was blessed to meet a great teacher in the guise of a patient early in my academic career. He came to my clinic in my first year after completing a Fellowship in Surgical Oncology, my first year as an Assistant Professor of Surgery. My patient was a 69 year-old Baptist Minister from a small town in Mississippi. He was referred to me by his medical oncologist who called me and said, “I don’t think there is anything you can do for him, but he needs to hear that from you because he doesn’t believe me.” This tall, imposing man had colon cancer that had metastasized (spread) to his liver. The malignant tumor in his colon was removed the year before I met him, and he had received chemotherapy to treat several large tumors found in his liver. The chemotherapy had not worked and the tumors grew. At the point I met him, the medical oncologist told him he would live no more than 6 months, and because he was an avid fisherman when not preaching or helping others in his community , the doctor suggested that he go out and enjoy his remaining time by getting in as much fishing as possible. I learned two invaluable lessons from this patient and his family. First, never deny or dismiss hope from a patient or their family, even when from a medical perspective the situation seems hopeless and the patient is incurable. Second, quoting the minister directly, “Some doctors think of themselves as gods with a small ‘g’, but not one of you is God”.

Continue reading “The Importance of Hope” »

American woman gets biologically younger after gene therapies.

Elizabeth Parrish, CEO of Bioviva USA Inc. has become the first human being to be successfully rejuvenated by gene therapy, after her own company’s experimental therapies reversed 20 years of normal telomere shortening.

Telomere score is calculated according to telomere length of white blood cells (T-lymphocytes). This result is based on the average T-lymphocyte telomere length compared to the American population at the same age range. The higher the telomere score, the “younger” the cells.

Continue reading “First gene therapy successful against human aging” »

Many think author, inventor and data scientist Ray Kurzweil is a prophet for our digital age. A few say he’s completely nuts. Kurzweil, who heads a team of more than 40 as a director of engineering at Google, believes advances in technology and medicine are pushing us toward what he calls the Singularity, a period of profound cultural and evolutionary change in which computers will outthink the brain and allow people—you, me, the guy with the man-bun ahead of you at Starbucks—to live forever. He dates this development at 2045.

Raymond Kurzweil was born February 12, 1948, and he still carries the plain, nasal inflection of his native Queens, New York. His Jewish parents escaped Hitler’s Austria, but Kurzweil grew up attending a Unitarian church. He worshipped knowledge above all, and computers in particular. His grandmother was one of the first women in Europe to earn a Ph.D. in chemistry. His uncle, who worked at Bell Labs, taught Ray computer science in the 1950s, and by the age of 15, Kurzweil was designing programs to help do homework. Two years later, he wrote code to analyze and create music in the style of various famous composers. The program won him the prestigious Westinghouse Science Talent Search, a prize that got the 17-year-old an invitation to the White House. That year, on the game show I’ve Got a Secret, Kurzweil pressed some buttons on a data processor the size of a small car. It coughed out original sheet music that could have been written by Brahms.

After earning degrees in computer science and creative writing at MIT, he began to sell his inventions, including the first optical character recognition system that could read text in any normal font. Kurzweil knew a “reading machine” could help the blind, but to make it work, he first had to invent a text-to-speech synthesizer, as well as a flatbed scanner; both are still in wide use. In the 1980s Kurzweil created the first electronic music keyboard to replicate the sound of a grand piano and many other instruments. If you’ve ever been to a rock concert, you’ve likely seen the name Kurzweil on the back of a synthesizer.

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.

This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.

Continue reading “Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study” »

Taking their cue from salamander regeneration, a team led by the University of New South Wales says that a stem cell therapy capable of regenerating any human tissue damaged by injury, disease, or aging could be available within a few years, thanks to an innovative new technique.

While stem cells have worked wonders in medicinal research, showing signs of curing everything from spinal cord injuries to blindness, they’ve always had their shortcomings. But one study is promising a new “game changing” technique for stem cells.

Taking their cue from salamander regeneration, new research led by the University of New South Wales says that a stem cell therapy capable of regenerating any human tissue damaged by injury, disease, or aging could be available within a few years, through an innovative new technique.

Awesome; could be a new track for reverse aging.

DARPA taking on the designer viruses and resistant fighting viruses that we hate. Who knows; they may finally find the fountain of youth in the process.

Vaccines are great, but they’re no match for most viruses in play at any given time. This is due largely in part to the ever-changing nature of viruses and the expense and difficulty in developing new vaccines to target them. DARPA wants that reality to change, citing the numerous concerning viruses, past and present, that affect humanity. Under the “INTERCEPT” program, DARPA seeks “shape-shifting” vaccines that adapt to kill off viruses as they evolve.

One of the biggest virus scares at the moment is the zika virus, but ebola was just recently a big issue and other viruses, including influenza and dengue, are a continuous problem. Once someone is infected, the virus is able to “mutate and morph as they reproduce inside their hosts,” says DARPA, making any vaccines quickly obsolete. If the agency’s new INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program proves successful, though, things will change in a big way.

Continue reading “DARPA wants ‘shape-shifting’ vaccines that evolve with viruses” »